The oyster-derived peptide （EVPPEEH） with higher zinc ion binding capacity was prepared by a proteinoid reaction （Plastein） modification with a zinc binding capacity of 161 mg/g. Zinc-deficient SD rats were used as experimental models， and oyster zinc-binding peptide OPZ and zinc-binding peptide modified by plastein reaction LPZ and ZnSO4（ZS） were used as control to study the vivo bioavailability and bioavailability of the oyster-derived metal chelating （EVPPEEH） and zinc conjugate （MZ）. The results showed that the levels of serum zinc， the reserves of femoral zinc and the contents of zinc in the liver and the kidneys in MZ group were significantly higher than those in the control group. Spleen zinc levels MZ group and LPZ group similar recovery， were significantly higher than OPZ group and ZS group. The body weight and food intake of MZ group and each control group were significantly increased， the effect is similar. The expression of ZnT1 in small intestine was not significantly different between MZ group and inorganic Zn group， while the expression of PepT1 was the highest in MZ group， which was 20% higher than that in ZS group， which was significantly higher than that in ZS group each control group. This shows that the absorption and utilization of MZ by the small intestine of rats are partly through the traditional zinc ion pathway and partly through the small peptide pathway. MZ is expected to become a new and efficient zinc supplement.